A great number of psoriasis patients go untreated with an average diagnosis time of five years according to a new study conducted by the Technical University of Munich, Germany. The Problem—Psoriasis Psoriasis is a common, noncommunicable skin disease with at least...
Psoriasis
Category
Radboud University Researchers & International Consortium Study Malaria Drug
Dutch researchers from Radboud University Medical Center collaborated with TropIQ, a Nijmegen-based spin-off and other researchers report that a molecule once designed to cure the skin disease psoriasis appears to be particularly effective against malaria—the...
Hospital Angeles Leads the Clinical Trial Investigating the Safety & Efficacy of NKMax’s SNK01 in Patients with Plaque Psoriasis
Angeles Hospital, a private state-of-the-art hospital in Tijuana, Mexico is conducting a clinical trial on behalf of Irvine, CA biotech sponsor NKMax America (part of Korean Parent) and just announced it treated the first participant in the study of SNK01-MX03, a...
XBiotech Talks With us About Their Upcoming Pipeline for Hidradenitis Suppurativa | Podcast
We had several requests from our Hidradenitis Suppurativa readers to do a follow up on the article "Is XBiotech on the Cusp of a Superior Hidradenitis Suppurativa Treatment?" So we asked XBiotech if they would be willing to sit down and talk with us about their...
Janssen Announces Positive Results from Phase 3 Guselkumab PsA Trial
Janssen reveals positive top-line results from two phase 3 trials of Tremfya (guselkumab) in patients with moderate to severe arthritis (PsA). Guselkumab is a human monoclonal antibody that blocks the p19 subunit of interleukin (IL)-23. The DISCOVER-1 (N=381) and...
Seoul St. Mary’s Hospital in Korea Connects Psoriasis with Risk of Mental Health Disorders
A team of Seoul St. Mary’s Hospital investigators utilizing population health data, involving over 1 million patients over 10 years, found evidence of a 2X increase of mental health disorders associated with psoriasis. These mental health issues include: Depressive...
Beth Israel Deaconess Observational Study Reveals Some Biologic Psoriasis Treatments Superior
Beth Israel Deaconess Medical Center conducted an observational cohort study, finding less risk of serious infection in patients taking newer targeted systemic medications for psoriasis as recently reported in EurekAlert! A common chronic skin condition...
Hallym University Korea Investigators Reveal Psoriasis Increases Risk of Migraine
Researchers from Hallym University and supporting Korean institutions sought to investigate the association of migraines to the autoimmune disorder of psoriasis. Both are inflammatory diseases. However, the investigators noted few prior studies were conducted...
Zucker School of Medicine Study Finds Hidradenitis Suppurativa Comorbidity Higher Vs. Psoriasis
Zucker School of Medicine at Hofstra/Northwell, New Hyde, New York conducted a study comparing psoriasis patients and healthy individuals with patients with hidradenitis suppurative (HS). The study results reveal that those with HS have a higher overall comorbidity...
AbbVie’s Treatment for Plaque Psoriasis, Skyrizi, Approved by FDA
AbbVie announced the FDA approved Skyrizi (risankizumab-rzaa), an interleukin-23 (IL-23) inhibitor, for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. The FDA approval of Skyrizi was based on...
AbbVie Treatment Approved For Moderate to Severe Psoriasis
Psoriasis afflicts approximately 7.5 million Americans and represents the most prevalent autoimmune disease in the United States reports drug producer AbbVie. In response, the Chicago-based industry sponsor has developed risankizumab-rzaa (SKYRIZI™), also known as...
Otezla; An Introduction
An estimated 7.5 million live with psoriasis in the United States alone. An autoimmune disease that surfaces on the skin as raised, red itchy patches, it starts inside the body. An estimated 79 million struggle with the genetic disease that can be triggered by...
PharmaWatch: Novartis Receives Approval for Psoriasis Drug Cosentyx in China
Nasdaq reports that the China Health Authority NMPA approved its blockbuster psoriasis drug, Cosentyx. A first-in-class interleukin 17A(IL-17A) inhibitor, it is the first biologic approved in China for moderate to severe plaque psoriasis in adult patients who are...
Sourasky Medical Centre to Execute Study for OWC Pharma
BiospectrumAsia reports OWC Pharmaceutical Research Corp. (the company transforming cannabis into scientifically proven and clinically approved medical solutions) announces an agreement with the Tel Aviv Sourasky Medical centre Fund. The medical centre will perform a...
Psoriasis Patient Takes Autoimmune Disorder to Facebook Live and Shares Struggles
As reported in WNEM by Coty Kuschinsky, Randi O’Connor has taken her battle with Psoriasis, what she thought was a skin disorder, to Facebook Live to chronicle the situation. Psoriasis, an autoimmune disease, speeds up the lifecycle of dead skin cells. The extra skin...
Novartis Joins TARGET PharmaSolutions for Longitudinal Dermatology Study with DNA BioBank
Novartis and TARGET PharmaSolutions jointly issued a press release touting that Novartis is the first industry partner to provide multi-year support for the development of the TARGET-DERM registry. Published in ClincialTrials.gov, TARGET-DERM is a 5-year,...
UCB’s Bimekizumab Demonstrates Positive Results from BE ABLE Study
What is the BE ABLE Studies? Global biopharmaceutical company recently presented results from their Phase 2b BE ABLE extension study of bimekizumab in patients with moderate-to-severe chronic plaque psoriasis, which shows nearly all BE ABLE 1 responders completing 60...
NHLBI Study Finds Biologic Drugs May Prevent Heart Disease in Patients with Severe Psoriasis
The National Heart, Lung and Blood Institute (part of the National Institutes of Health) reports that an anti-inflammatory drug commonly used to treat severe psoriasis also improve plaque in the coronary artery making them more stable and less likely to cause heart...
Study Links Psoriasis Treatment With Improvement in Heart Artery Disease
The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH) has funded an innovative study revealing that the treatment of psoriasis with biologic drugs that target immune system activity can reduce the early plaque buildup...
USC Research Finds Psoriasis Online Care Delivery Model Equivalent to In-Person
As reported in EurekAlert!, for approximately eight million Americans, visiting a doctor regularly is the key to managing their psoriasis, a chronic inflammatory skin condition characterized by itchy or painful red patches that can appear anywhere on the body. But for...